LucidScope
AI is already answering questions about your brand. LucidScope shows you what it’s saying, and why.
LucidScope evaluates how leading AI systems respond to real-world questions about your company, products, indications, and competitors.
It maps visibility and positioning in AI-generated answers, traces the sources shaping those answers, and highlights gaps where evidence is missing, outdated, or misrepresented.
What you can do with LucidScope:
-
Perception Mapping: Compare how AI positions your brand versus key competitors.
- See how AI frames your brand versus competitors, by theme and attribute.
-
Answers Mapping: See how models answer the same stakeholder questions, and where they diverge.
- View side-by-side model answers to your key questions, with differences highlighted.
-
Source Tracing: Identify which websites and documents are shaping AI answers, and where to intervene.
- Understand which domains and documents drive the answers, and what’s missing.
-
Launch and campaign monitoring: Track changes over time across models, markets, and topics.
- Monitor shifts in positioning, key claims, and cited sources (you vs competitors).
LucidScope is part of LucidQuest’s intelligence stack, complementing our primary research, conference coverage, and wargaming capabilities.
Combined with NexusBrain (nexusbrain.io), LucidScope insights can be mapped alongside your team’s own field observations to give a complete picture of how AI is shaping your brand’s perception.
Want to see what AI is saying about your brand? Request an AI Answer Audit.
You’ll receive a short report covering Perception, Answers, Source Tracing, and Zero-click gaps.
Already evaluating tools? Test LucidScope.
Questions or feedback? Email us anytime.
February 9, 2026
Lucid Diligence Brief: Innovent – Eli Lilly Global R&D Alliance
February 9, 2026
Hematology Video Recap—February 9, 2026
February 9, 2026
Hematology Today—February 9, 2026
February 9, 2026
Oncology Today—February 9, 2026
February 9, 2026
AI in Healthcare and Digital Health Today—February 9, 2026
February 8, 2026
Lucid Diligence Brief: uniQure AMT-191 Fabry dosing pause
February 7, 2026
Lucid Diligence Brief: Angitia Biopharmaceuticals $130 million Series D
February 6, 2026
Vaccines Video Recap—February 6, 2026
February 6, 2026
Respiratory Video Recap—February 6, 2026
February 6, 2026
Public Health Today—February 6, 2026
February 6, 2026
Vaccines Today—February 6, 2026
February 6, 2026